Company news

Neurocrine Biosciences, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Neurocrine Biosciences to Spotlight Its Scientific Journey and Growing Neuropsychiatry Pipeline at 2026 NEI Fall Congress

November 3, 2026

Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results

November 2, 2026

Neurocrine Biosciences Launches Interactive Educational Resources to Support Clinical Learning in Classic Congenital Adrenal Hyperplasia

October 30, 2026

Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia

October 26, 2026

Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome

October 22, 2026

Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease

October 20, 2026

Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia

October 16, 2026

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results

October 12, 2026

Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference

September 30, 2026

Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer

September 28, 2026

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia

August 12, 2026

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist

August 7, 2026

Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results

July 30, 2026

Neurocrine Biosciences Announces Key Leadership Hiring, Promotions

July 23, 2026

Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer

July 21, 2026

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results

July 9, 2026

Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia

July 1, 2026

Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period

June 15, 2026

Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026

June 15, 2026

Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026

June 15, 2026

Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026

June 15, 2026

Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities

June 8, 2026

Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026

June 3, 2026

Neurocrine Biosciences to Present at Upcoming Investor Conferences in June

May 26, 2026

Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules

May 18, 2026

Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics

May 18, 2026

Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia

May 6, 2026

Neurocrine Biosciences Reports First-Quarter 2026 Financial Results

May 5, 2026

Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026

May 5, 2026

Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment

May 4, 2026

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist

May 4, 2026

Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia

May 1, 2026

Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale

April 29, 2026

Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia

April 22, 2026

2026 Proxy Statement (NBIX 2026 Proxy Statement)

April 15, 2026

2025 Annual Report*

April 15, 2026

Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR

April 14, 2026

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results

April 13, 2026

Nxera Pharma’s Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia

April 12, 2026

Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio

April 5, 2026

Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings

March 25, 2026

Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer

March 16, 2026

Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum

March 9, 2026

Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026

February 11, 2026

Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia

January 26, 2026

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results

January 21, 2026

Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR

January 15, 2026

Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 4, 2026

Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy

December 21, 2025

Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology

December 15, 2025

Older news releases →

Calls

The 5 newest of 17 calls. Every call is listed under its year.

Decks

The 5 newest of 16 decks. Every deck is listed under its year.